Abstract
The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
3,4-Dihydroxyphenylacetic Acid / metabolism
-
Animals
-
Corpus Striatum / drug effects
-
Corpus Striatum / metabolism
-
Dopamine / metabolism*
-
Dose-Response Relationship, Drug
-
Male
-
Nicotine / pharmacology*
-
Nicotinic Agonists / pharmacology
-
Nicotinic Antagonists / administration & dosage
-
Nicotinic Antagonists / pharmacology*
-
Nucleus Accumbens / drug effects
-
Nucleus Accumbens / metabolism
-
Picolines / administration & dosage
-
Picolines / pharmacology*
-
Prefrontal Cortex / drug effects
-
Prefrontal Cortex / metabolism
-
Rats
-
Rats, Sprague-Dawley
Substances
-
N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide
-
Nicotinic Agonists
-
Nicotinic Antagonists
-
Picolines
-
3,4-Dihydroxyphenylacetic Acid
-
Nicotine
-
Dopamine